San Francisco-based pharmaceuticals company, Jaguar Health, Inc., has established itself as a major player in the treatment of gastrointestinal distress, with a particular focus on chronic and debilitating diarrhea. As part of its drive to develop prescription medicines that treat both people and animals, the company operates through two separate segments: Human Health and Animal Health. One of its flagship products is Mytesi, which is utilized for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS who are undergoing antiretroviral therapy. Jaguar Health is also currently developing Crofelemer, which is currently in Phase 3 clinical trials for the prophylaxis of diarrhea in adult cancer patients, as well as targeting rare and orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders. Other drugs in Jaguar Health's portfolio include NP-300, a second-generation anti-secretory antidiarrheal drug, and Canalevia, an oral plant-based drug candidate designed to alleviate chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Since being founded in 2013, Jaguar Health has developed an impressive track record for innovation and excellence within the fast-moving world of pharmaceuticals.
Jaguar Health's ticker is JAGX
The company's shares trade on the NASDAQ stock exchange
They are based in San Francisco, California
There are 11-50 employees working at Jaguar Health
It is jaguar.health
Jaguar Health is in the Healthcare sector
Jaguar Health is in the Biotechnology industry
The following five companies are Jaguar Health's industry peers: